302 related articles for article (PubMed ID: 20854964)
21. Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension.
Tuncer M; Guntekin U; Gunes Y; Gumrukcuoglu HA; Eryonucu B
Adv Ther; 2008 Jun; 25(6):619-26. PubMed ID: 18563311
[TBL] [Abstract][Full Text] [Related]
22. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Olsen MH; Wachtell K; Bella JN; Palmieri V; Gerdts E; Smith G; Nieminen MS; Dahlöf B; Ibsen H; Devereux RB
Am J Hypertens; 2005 Nov; 18(11):1430-6. PubMed ID: 16280277
[TBL] [Abstract][Full Text] [Related]
23. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Wachtell K; Papademetriou V; Smith G; Gerdts E; Dahlöf B; Engblom E; Aurigemma GP; Bella JN; Ibsen H; Rokkedal J; Devereux RB
Am Heart J; 2004 Sep; 148(3):538-44. PubMed ID: 15389245
[TBL] [Abstract][Full Text] [Related]
24. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Reims HM; Kjeldsen SE; Brady WE; Dahlöf B; Devereux RB; Julius S; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hum Hypertens; 2004 Jun; 18(6):381-9. PubMed ID: 15103313
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
26. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
[TBL] [Abstract][Full Text] [Related]
27. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Kjeldsen SE; Devereux RB; Hille DA; Lyle PA; Dahlöf B; Julius S; Edelman JM; Snapinn SM; de Faire U; Fyhrquist F; Ibsen H; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Blood Press; 2009; 18(6):348-61. PubMed ID: 20001655
[TBL] [Abstract][Full Text] [Related]
28. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
[TBL] [Abstract][Full Text] [Related]
29. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Gerdts E; de Simone G; Lund BP; Okin PM; Wachtell K; Boman K; Nieminen MS; Dahlöf B; Devereux RB
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):122-9. PubMed ID: 21775111
[TBL] [Abstract][Full Text] [Related]
30. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
[TBL] [Abstract][Full Text] [Related]
31. Treatment of diastolic dysfunction in hypertension.
Ginelli P; Bella JN
Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):613-8. PubMed ID: 22743209
[TBL] [Abstract][Full Text] [Related]
32. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
Am J Hypertens; 2012 Oct; 25(10):1101-9. PubMed ID: 22717544
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
[TBL] [Abstract][Full Text] [Related]
34. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
[TBL] [Abstract][Full Text] [Related]
35. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
Gerdts E; Cramariuc D; de Simone G; Wachtell K; Dahlöf B; Devereux RB
Eur J Echocardiogr; 2008 Nov; 9(6):809-15. PubMed ID: 18490279
[TBL] [Abstract][Full Text] [Related]
36. In-treatment stroke volume predicts cardiovascular risk in hypertension.
Lønnebakken MT; Gerdts E; Boman K; Wachtell K; Dahlöf B; Devereux RB
J Hypertens; 2011 Aug; 29(8):1508-14. PubMed ID: 21720264
[TBL] [Abstract][Full Text] [Related]
37. Effect of changing heart rate during treatment of hypertension on incidence of heart failure.
Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Devereux RB
Am J Cardiol; 2012 Mar; 109(5):699-704. PubMed ID: 22154318
[TBL] [Abstract][Full Text] [Related]
38. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Mancusi C; Gerdts E; de Simone G; Midtbø H; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
Blood Press; 2017 Jun; 26(3):150-155. PubMed ID: 27710139
[TBL] [Abstract][Full Text] [Related]
39. Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension.
Ye P; Wu CE; Sheng L; Li H
J Altern Complement Med; 2009 Jul; 15(7):719-25. PubMed ID: 19552598
[TBL] [Abstract][Full Text] [Related]
40. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
